Skip to main content
. 2026 Mar 10;18(6):890. doi: 10.3390/cancers18060890
ASCO American Society of Clinical Oncology
BMI Body Mass Index
CAFs Cancer-associated fibroblasts
CAT Cancer-associated thrombosis
CrCl Creatinine clearance
CRNMB Clinically relevant non-major bleeding
CT Computed tomography
DOACs Direct oral anticoagulants
DVT Deep venous thrombosis
EMT Epithelial-to-mesenchymal transition
ESMO European Society For Medical Oncology
FXI Factor XI
GEM Gemcitabine
FEMWAD Gemcitabine with weight-adjusted dalteparin
GI Gastrointestinal
GU Genitourinary
Hb Hemoglobin
IL-8 Interleukin 8
ITAC International Initiative on Thrombosis and Cancer
IVE Inferior vena cava
LMWH Low-molecular-weight heparin
MB Major bleeding
MVs Microvesicles
NETs Neutrophil extracellular traps
OS Overall survival
PAI-1 Plasminogen activator inhibitor type 1
PAR Protease-activated receptors
PC Pancreatic cancer
PDAC Pancreatic ductal adenocarcinoma
PDGF Platelet-derived growth factor
PDPN Podoplanin
PE Pulmonary embolism
PFS Progression-free survival
PF4 Platelet factor 4
PLT Platelet
RBC Red blood cell
TEC Thromboembolic complications
TF Tissue factor
TFPI Tissue factor pathway inhibitor
TNF-a Tumor necrosis factor a
UFH Unfractionated heparin
VKA Vitamin K antagonist
VTE Venous thromboembolism
WBC White blood cell
VEGF Vascular endothelial growth factor